Captozyme’s staff of scientists, researchers, and engineers embody passion, energy and confidence. They are constantly working to push the question “Why” in their research and bring new discoveries to life.
Our product development pipeline of future products focuses on enzymes and live biotherapeutics to treat diseases through the gut.
A0 is a proprietary orally administered recombinant oxalate decarboxylase (OxDC) enzyme from Agrocybe aegerita, designed to degrade oxalate at different pH ranges throughout the entire length of the gastrointestinal tract (GI tract).
World COngress of Endourology abstract
In September 2018, an abstract and poster featuring Captozyme and our A0 research were presented at the 2018 World Congress of Endourology in Paris. The abstract on Reduction of Urinary Oxalate by Enzymatic Reduction of Dietary and Endogenous Oxalate explored the potential development of an oral agent utilizing A0 to intercept oxalate in both the stomach (diet) and the intestines (endogenous).